Drug interactions modulate the potential for evolution of resistance

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 39, 2008, Pages 14918-14923

  Michel, Jean Baptiste ^a,b   Yeh, Pamela J ^a   Chait, Remy ^a   Moellering Jr , Robert C ^c   Kishony, Roy ^a,d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

Antibiotic resistance; Drug combinations; Epistasis; Mutant selection window; Staphylococcus aureus

Indexed keywords

AMIKACIN; AMPICILLIN; CIPROFLOXACIN; ERYTHROMYCIN; FUSIDIC ACID; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CROSS RESISTANCE; DRUG INTERACTION; DRUG RESISTANCE; EPISTASIS; EVOLUTION; EXPERIMENTAL STUDY; IMAGING; MATHEMATICAL MODEL; MODULATION; MULTIDRUG RESISTANCE; MUTANT; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; THEORY; WILD TYPE; CYTOLOGY; DRUG EFFECT; GENETIC EPISTASIS; GENETICS; MOLECULAR EVOLUTION;

STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPISTASIS, GENETIC; EVOLUTION, MOLECULAR; STAPHYLOCOCCUS AUREUS;

EID: 54449092082     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0800944105     Document Type: Article

References (40)

1. Austin DJ, Kristinsson KG, Anderson RM (1999) The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 96:1152-1156.
2. Wang YC, Lipsitch M (2006) Upgrading antibiotic use within a class: Tradeoff between resistance and treatment success. Proc Natl Acad Sci USA 103:9655-9660.
3. Martínez JL, Baquero F, Andersson DI (2007) Predicting antibiotic resistance. Nat Rev Microbiol 5:958-965.
4. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585-615.
5. Loewe S (1928) The quantitative problems of pharmacology (Translated from German). Ergebn Phsyiol 27:47-187.
6. Greco WR, Bravo G, Parsons JC (1995) The search for synergy - A critical-review from a response surface perspective. Pharmacol Rev 47:331-385.
7. Hartman JL, Garvik B, Hartwell L (2001) Cell biology - Principles for the buffering of genetic variation. Science 291:1001-1004.
8. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446:668-671.
9. Fauci AS (2003) HIV and AIDS: 20 years of science. Nat Med 9:839-843.
10. Bhusal Y, Shiohira CM, Yamane N (2005) Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 26:292-297.
11. Edwards G, Biagini GA (2006) Resisting resistance: Dealing with the irrepressible problem of malaria. Br J Clin Pharmacol 61:690-693.
12. White NJ, et al. (1999) Averting a malaria disaster. Lancet 353:1965-1967.
13. Gollob JA, et al. (2007) Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25:3288-3295.
14. Moran GJ, et al. (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674.
15. Kucers A, Crowe S, Grayson ML, Hoy J (1997) The Use of Antibiotics (Butterworth-Heinemann, Oxford).
16. Moellering RJ (2008) Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46:1032-1037.
17. Bull JJ, Wichman HA (2001) Applied evolution. Annu Rev Ecol Syst 32:183-217.
18. Pankey GA, Sabath LD (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 38:864-870.
19. Dong YZ, Zhao XL, Domagala J, Drlica K (1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43:1756-1758.
20. Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52:11-17.
21. Sindelar G, et al. (2000) Mutant prevention concentration as ameasure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 44:3337-3343.
22. Blondeau JM, Zhao XL, Hansen G, Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:433-438.
23. Linde HJ, Lehn N (2004) Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 53:252-257.
24. Metzler K, et al. (2004) Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 24:161-167.
25. Randall LP, Cooles SW, Piddock LJV, Woodward MJ (2004) Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. J Antimicrob Chemother 54:688-691.
26. Marcusson LL, Olofsson SK, Lindgren PK, Cars O, Hughes D (2005) Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55:938-943.
27. Zhao X, Drlica K (2002) Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the Mutant Selection Window. J Infect Dis 185:561-565.
28. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94:12106-12111.
29. Pillai SK, Moellering RC, Eliopoulos GM (2005) in Antibiotics in Laboratory Medicine, ed Lorian V (Lippincott Williams & Wilkins, Philadelphia), pp 365-440.
30. Fishman N (2006) Antimicrobial stewardship. Am J Med 119:S53-S61.
31. Henderson DK (2006) Managing methicillin-resistant staphylococci: A paradigm for preventing nosocomial transmission of resistant organisms. Am J Med 119:S45-S52.
32. McGowan JE (2006) Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum. Am J Med 119:S29-S36.
33. Rybak MJ (2006) Pharmacodynamics: Relation to antimicrobial resistance. Am J Med 119:S37-S44.
34. Walsh C (2003) Antibiotics: Actions, Origins, Resistance (Am Soc Microbiol, Washington, DC).
35. Drusano GL (2004) Antimicrobial pharmacodynamics: Critical interactions of "bug and drug." Nat Rev Microbiol 2:289-300.
36. Andersson DI (2003) Persistence of antibiotic resistant bacteria. Curr Opin Microbiol 6:452-456.
37. Duthie ES, Lorenz LL (1952) Staphylococcal coagulase - Mode of action and antigenicity. J Gen Microbiol 6:95-107.
38. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 55: 601-607.
39. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38:489-494.
40. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. (2004) Bacterial peristence as a phenotypic switch. Science 305:1622-1625.